Tounjian Advisory Partners’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
Other funds holding REGN
Tounjian Advisory Partners's REGN Position: Q2 2026 in Review
Tounjian Advisory Partners opened a new position in Regeneron Pharmaceuticals (REGN) in Q2 2026: 2 shares worth $1.25K. The stake represents ﹤0.01% of the portfolio and ranks #635 among its holdings. This is a return to the name: Tounjian Advisory Partners previously reported a position in REGN as recently as Q2 2025.
Tounjian Advisory Partners first reported a position in REGN in Q1 2025 and has held it in 3 quarters since. The position peaked at $662K in Q1 2025. 1,340 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Tounjian Advisory Partners held 2 shares of Regeneron Pharmaceuticals worth $1.25K as of Q2 2026.
- Regeneron Pharmaceuticals was a new Tounjian Advisory Partners position in Q2 2026.
- Regeneron Pharmaceuticals made up ﹤0.01% of Tounjian Advisory Partners's portfolio in Q2 2026, its #635 holding.
- Tounjian Advisory Partners first reported a position in Regeneron Pharmaceuticals in Q1 2025 and has held it in 3 quarters since.
- Tounjian Advisory Partners's Regeneron Pharmaceuticals position peaked at $662K in Q1 2025.
- 1,340 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Tounjian Advisory Partners's 13F filing for Q2 2026, filed 7 Aug 2026.